Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar… - JAMA …, 2018 - jamanetwork.com
Importance Hyperprogressive disease (HPD) is a new pattern of progression recently
described in patients with cancer treated with programmed cell death 1 (PD-1) and
programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in
advanced non–small cell lung cancer (NSCLC) are unknown. Objectives To investigate
whether HPD is observed in patients with advanced NSCLC treated with PD-1/PD-L1
inhibitors compared with single-agent chemotherapy and whether there is an association …
described in patients with cancer treated with programmed cell death 1 (PD-1) and
programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in
advanced non–small cell lung cancer (NSCLC) are unknown. Objectives To investigate
whether HPD is observed in patients with advanced NSCLC treated with PD-1/PD-L1
inhibitors compared with single-agent chemotherapy and whether there is an association …